Billing Codes Confirmed for Monkeypox Tests and Vaccines
The American Medical Association (AMA) recently announced an update to Current Procedural Terminology (CPT)® that includes a new laboratory test code for the orthopoxvirus and two codes for the vaccines utilized to prevent monkeypox infection.
These new CPT codes are important to ensure people are charged, or not, for these services in the USA.
The new laboratory test CPT code (87593) describes molecular diagnostic testing that detects the nucleic signature of an orthopoxvirus, including the monkeypox virus.
And the two new vaccine codes are designed to describe the two smallpox and monkeypox virus products currently available.
The first code (90622) describes the existing FDA-approved ACAM2000 vaccine manufactured by Sanofi Pastuer Biologics Co. for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection.
The second code (90611) describes the FDA-approved JYNNEOS vaccine manufactured by Bavarian Nordic to prevent smallpox and monkeypox disease in adults 18 years of age and older at high risk for smallpox or monkeypox infection.
"In the wake of the WHO declaring monkeypox a global health emergency, and with case numbers increasing in the United States, these CPT updates are timely," said AMA President Jack Resneck Jr., M.D., in a press release on July 26, 2022.
"The daily increase in cases in the USA shows community spread occurring."
"However, we are relieved to see access to testing has increased to 80,000 specimens per week with commercial labs now online, and vaccine supply is increasing."
"Monkeypox is most often spread from person to person through close personal contact, but preventive measures can help you avoid infection."
"We urge patients to check trusted, evidence-based sources like the CDC and AMA and to contact their physician if they have questions about prevention, diagnosis, or treatment of monkeypox."
Note: This AMA press release was manually curated for mobile readers.